文献速递肾小球疾病急性肾损伤

抗肾小球基底膜病:亚组、发病机制与治疗进展

Anti-glomerular basement membrane disease: an update on subgroups, pathogenesis and therapies.
PubMed 文献 · Nephrol Dial Transplant · 2019-01-01

抗肾小球基底膜病多表现为急进性肾小球肾炎,可伴肺出血,但存在多种变异型需警惕。几乎所有患者自身抗体识别IV型胶原α3链两个表位,HLA-DR15抗原缺乏促Treg发育能力。快速检测有助早期诊断,但现有治疗不足,仅约三分之一患者保留肾功能,需开发新疗法。

要点

  • 抗GBM病可表现为孤立肺出血或循环抗体阴性,需警惕变异型。
  • HLA-DR15抗原缺乏促Treg发育能力,与疾病易感相关。
  • 快速检测有助早期诊断,但仅约三分之一患者保留自身肾功能。

核心结论

  • 抗GBM病存在多种变异型,需警惕以避免误诊。
  • 几乎所有患者自身抗体识别IV型胶原α3链两个表位。
  • 现有治疗不足,仅约三分之一患者保留自身肾功能。

研究设计与样本

  • 综述,总结抗GBM病的亚组、发病机制与治疗进展。

主要发现

  • 抗GBM病可与ANCA相关血管炎或膜性肾病重叠,也可肾移植后新发。
  • 患者可表现为孤立肺出血或循环抗GBM抗体阴性。
  • 健康人存在低亲和力天然抗体,但HLA依赖的Tregs保护多数人不产生致病性高亲和力自身抗体。
  • HLA-DR15抗原呈递的α3链肽段缺乏促Treg发育能力。
  • 快速检测循环抗GBM有助早期诊断和改善预后。

关键数值与推荐

  • 仅约三分之一患者存活且保留自身肾功能。

临床怎么用

  • 对疑似抗GBM病应警惕变异型,包括抗体阴性或孤立肺出血。
  • 快速检测循环抗GBM有助于早期诊断。
  • 现有治疗不足以控制炎症和清除致病抗体,需探索新疗法。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Most patients with anti-glomerular basement membrane (anti-GBM) disease present with rapidly progressive glomerulonephritis with or without pulmonary haemorrhage; however, there are several variants and vigilance is necessary to make a correct diagnosis. Such variants include overlap with anti-neutrophil cytoplasm antibodies-associated vasculitis and membranous nephropathy as well as anti-GBM occurring de novo after renal transplantation. Moreover, patients can present with isolated pulmonary haemorrhage as well as with negative tests for circulating anti-GBM. Virtually all patients with anti-GBM disease have autoantibodies that react with two discrete epitopes on the α3 chain of type IV collagen. Recent evidence suggests that healthy persons have low-affinity natural antibodies reacting with the same epitopes, but most people are protected from developing disease-causing high-affinity autoantibodies by human leukocyte antigen-dependent regulatory T-cells (Tregs). The α3 chain-derived peptides presented by the HLA-DR15 antigen lack the ability to promote the development of such Tregs. The detection of anti-GBM in circulation using the rapid assay test has led to early diagnosis and improved prognosis. However, our present tools to curb the inflammation and to eliminate the assaulting antibodies are insufficient. Only about one-third of all patients survive with functioning native kidneys. More effective therapies need to be developed; agents that inhibit neutrophil recruitment, deplete B cells and cleave immunoglobulin G (IgG) in vivo may become new weapons in the arsenal to combat anti-GBM disease.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Segelmark M, Hellmark T. Anti-glomerular basement membrane disease: an update on subgroups, pathogenesis and therapies. Nephrol Dial Transplant. 2019. PMID: 30371823. doi:10.1093/ndt/gfy327

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。